Citation: Humayra Afrin, Christiancel Joseph Salazar, Mohsin Kazi, Syed Rizwan Ahamad, Majed Alharbi, Md Nurunnabi. Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics[J]. Chinese Chemical Letters, ;2022, 33(6): 2773-2782. doi: 10.1016/j.cclet.2022.01.011 shu

Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics

Humayra Afrin ^{a, b, f} ,
Christiancel Joseph Salazar ^{a, b} ,
Mohsin Kazi ^{c, *,} ,
Syed Rizwan Ahamad ^d ,
Majed Alharbi ^c ,
Md Nurunnabi ^{a, b, e, f, *,}

a.
Environmental Science & Engineering, University of Texas at El Paso, El Paso, TX 79965, United States
b.
Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX 79965, United States
c.
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
d.
Central Laboratory, Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
e.
Department of Biomedical Engineering, University of Texas at El Paso, El Paso, TX 79965, United States
f.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, TX 79902, United States

mkazi@ksu.edu.sa

mnurunnabi@utep.edu

Received Date: 22 August 2021
Revised Date: 1 January 2022
Accepted Date: 7 January 2022
Available Online: 14 January 2022

Figures(4)

Cardiac toxicity is one of the most common side effects of anticancer drugs. Cardiac toxicity results dysfunction of heart including hypotension, heart failure, and even cause death in extreme cases. The potential risk of cardiotoxicity is a huge concern in chemotherapeutics mediated cancer treatment. The individual with any pre-existing cardiac issues are excluded from clinical trials due to the potential risk of cardiotoxicity. Because of the potential cardiotoxicity, there is an emerging need for alternatives of some very potent anticancer drugs (doxorubicin/DOX, 5-fluorouracil/5FU, trastuzumab). While a patient is being treated with anticancer drugs, early blood screening, biomarker detection, and careful monitoring of cardiac functions are necessary to be able to avoid any irreversible cardiac damage. Therefore, early detection methodology to monitor cardiotoxicity in real-time, and a drug formulation that prevent interaction between drug and cardiac cell, seemingly have potential to mitigate the risk. In this review, we have summarized the cardiotoxicity of the most used anticancer drugs, their pathophysiology and some of the conventional and newer screening methods available to manage an individual patient in clinic. We have also incorporated our perspective on how a rationale designing of biomolecules can be used to overcome the cardiotoxicity generated chemotherapeutics.
- Cardiotoxicity,
- Anticancer drug,
- Chemotherapy,
- Screening,
- Biomarker
1. [1]
  A.K. Peter, M.A. Bjerke, L.A. Leinwand, Mol. Biol. Cell. 27 (2016) 2149–2160. doi: 10.1091/mbc.E16-01-0038
2. [2]
  J. Dong, H. Chen, Front. Cardiovasc. Med. 5 (2018) 9. doi: 10.1051/limn/2017031
3. [3]
  A. Albini, G. Pennesi, F. Donatelli, et al., J. Natl. Cancer Inst. 102 (2010) 14–25. doi: 10.1093/jnci/djp440
4. [4]
  H.M. Chang, R. Moudgil, T. Scarabelli, T.M. Okwuosa, E.T.H. Yeh, J. Am. Coll. Cardiol. 70 (2017) 2536–2551. doi: 10.1016/j.jacc.2017.09.1096
5. [5]
  R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J. Clin. 71 (2021) 7–33. doi: 10.3322/caac.21654
6. [6]
  R.A. DePinho, Nature 408 (2000) 248–254. doi: 10.1038/35041694
7. [7]
  M.S. Ewer, S.M. Ewer, Nat. Rev. Cardiol. 7 (2010) 564–575. doi: 10.1038/nrcardio.2010.121
8. [8]
  S.H. Armenian, C. Lacchetti, A. Barac, et al., J. Clin. Oncol. 35 (2017) 893–911. doi: 10.1200/JCO.2016.70.5400
9. [9]
  G. Curigliano, D. Cardinale, S. Dent, et al., CA Cancer J. Clin. 66 (2016) 309–325. doi: 10.3322/caac.21341
10. [10]
  W. -. S. Lee, J. Kim, Mol. Cell. Toxicol. 14 (2018) 247–254. doi: 10.1007/s13273-018-0027-z
11. [11]
  M.S. Ewer, S.M. Ewer, Nat. Rev. Cardiol. 12 (2015) 547–558. doi: 10.1038/nrcardio.2015.65
12. [12]
  S. Geiger, V. Lange, P. Suhl, V. Heinemann, H.J. Stemmler, Anticancer Drugs21 (2010) 578–590. doi: 10.1097/CAD.0b013e3283394624
13. [13]
  I. Brana, E. Zamora, G. Oristrell, J. Tabernero, Cardiotoxicity, in: Side Eff. Med. Cancer Ther., Springer International Publishing, Cham, 2018, pp. 367–406.
14. [14]
  H. Wang, R.D. Robinson, C. Johnson, et al., BMC Cardiovasc. Disord. 14 (2014) 97. doi: 10.1186/1471-2261-14-97
15. [15]
  L.A. Smith, V.R. Cornelius, C.J. Plummer, et al., BMC Cancer10 (2010) 337. doi: 10.2746/042516406777749155
16. [16]
  M.S. Ewer, S.M. Lippman, J. Clin. Oncol. 23 (2005) 2900–2902. doi: 10.1200/JCO.2005.05.827
17. [17]
  S.M. Swain, F.S. Whaley, M.S. Ewer, Cancer 97 (2003) 2869–2879. doi: 10.1002/cncr.11407
18. [18]
  D.D. VON HOFF, Ann. Intern. Med. 91 (1979) 710. doi: 10.7326/0003-4819-91-5-710
19. [19]
  D. Tallarico, V. Rizzo, F. di Maio, et al., Angiology 54 (2003) 219–227. doi: 10.1177/000331970305400212
20. [20]
  R. Jurcut, H. Wildiers, J. Ganame, et al., Support. Care Cancer16 (2008) 437–445. doi: 10.1007/s00520-007-0397-6
21. [21]
  P.K. Singal, N. Iliskovic, N. Engl. J. Med. 339 (1998) 900–905. doi: 10.1056/NEJM199809243391307
22. [22]
  P.A. Henriksen, Heart104 (2018) 971–977. doi: 10.1136/heartjnl-2017-312103
23. [23]
  D. Cardinale, F. Iacopo, C.M. Cipolla, Front. Cardiovasc. Med. 7 (2020) 26. doi: 10.3389/fcvm.2020.00026
24. [24]
  J. V. McGowan, R. Chung, A. Maulik, et al., Cardiovasc. Drugs Ther. 31 (2017) 63–75. doi: 10.1007/s10557-016-6711-0
25. [25]
  O. Odiete, M.F. Hill, D.B. Sawyer, Circ. Res. 111 (2012) 1376–1385. doi: 10.1161/CIRCRESAHA.112.267286
26. [26]
  S. Zhang, X. Liu, T. Bawa-Khalfe, et al., Nat. Med. 18 (2012) 1639–1642. doi: 10.1038/nm.2919
27. [27]
  G.C. Pereira, S.P. Pereira, L.C. Tavares, et al., Mitochondrion. 30 (2016) 95–104. doi: 10.1016/j.mito.2016.07.005
28. [28]
  M. Volkova, R. Russell, Curr. Cardiol. Rev. 7 (2012) 214–220. doi: 10.2174/157340311799960645
29. [29]
  A. Ghigo, M. Li, E. Hirsch, Biochim. Biophys. Acta: Mol. Cell Res. 1863 (2016) 1916–1925. doi: 10.1016/j.bbamcr.2016.01.021
30. [30]
  G. Varricchi, P. Ameri, C. Cadeddu, et al., Front. Physiol. 9 (2018) 167. doi: 10.3389/fphys.2018.00167
31. [31]
  R.D. Olson, P.S. Mushlin, D.E. Brenner, et al., Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3585–3589. doi: 10.1073/pnas.85.10.3585
32. [32]
  R.D. Olson, P.S. Mushlin, FASEB J. 4 (1990) 3076–3086. doi: 10.1096/fasebj.4.13.2210154
33. [33]
  D.J. Slamon, B. Leyland-Jones, S. Shak, et al., N. Engl. J. Med. 344 (2001) 783–792. doi: 10.1056/NEJM200103153441101
34. [34]
  D. Slamon, G. Clark, S. Wong, et al., Science 235 (1987) 177–182. doi: 10.1126/science.3798106
35. [35]
  S.L. Lim, C.S.P. Lam, V.F.M. Segers, D.L. Brutsaert, G.W. De Keulenaer, Eur. Heart J. 36 (2015) 2050–2060. doi: 10.1093/eurheartj/ehv132
36. [36]
  T. Force, D.S. Krause, R.A. Van Etten, Nat. Rev. Cancer. 7 (2007) 332–344. doi: 10.1038/nrc2106
37. [37]
  R. Kerkelä, L. Grazette, R. Yacobi, et al., Nat. Med. 12 (2006) 908–916. doi: 10.1038/nm1446
38. [38]
  R.S. Vasan, D. Levy, M.G. Larson, E.J. Benjamin, Am. Heart J. 139 (2000) 412–422. doi: 10.1016/S0002-8703(00)90084-X
39. [39]
  D.B. Longley, D.P. Harkin, P.G. Johnston, Nat. Rev. Cancer. 3 (2003) 330–338. doi: 10.1038/nrc1074
40. [40]
  A. Polk, K. Vistisen, M. Vaage-Nilsen, D.L. Nielsen, BMC Pharmacol. Toxicol. 15 (2014) 47. doi: 10.1186/2050-6511-15-47
41. [41]
  F. Cheng, J. Loscalzo, Trends Immunol. 38 (2017) 77–78. doi: 10.1016/j.it.2016.11.007
42. [42]
  P. Waterhouse, J.M. Penninger, E. Timms, et al., Science 270 (1995) 985–988. doi: 10.1126/science.270.5238.985
43. [43]
  H. Nishimura, T. Okazaki, Y. Tanaka, et al., Science 291 (2001) 319–322. doi: 10.1126/science.291.5502.319
44. [44]
  M.L. Tarrio, N. Grabie, D. Bu, A.H. Sharpe, A.H. Lichtman, J. Immunol. 188 (2012) 4876–4884. doi: 10.4049/jimmunol.1200389
45. [45]
  V. Quagliariello, M. Passariello, C. Coppola, et al., Int. J. Cardiol. 292 (2019) 171–179. doi: 10.1016/j.ijcard.2019.05.028
46. [46]
  A. Narezkina, K. Nasim, Circ. Hear. Fail. 12 (2019) e005910. doi: 10.1161/CIRCHEARTFAILURE.119.005910
47. [47]
  C. Kelly, N. Bhuva, M. Harrison, A. Buckley, M. Saunders, Eur. J. Cancer. 49 (2013) 2303–2310. doi: 10.1016/j.ejca.2013.03.004
48. [48]
  J.D. Sara, J. Kaur, R. Khodadadi, et al., Ther. Adv. Med. Oncol. 10 (2018) 175883591878014.
49. [49]
  M.F. Sorrentino, J. Kim, A.E. Foderaro, A.G. Truesdell, Cardiol. J. 19 (2012) 453–457. doi: 10.5603/CJ.2012.0084
50. [50]
  M.W. Saif, M.M. Shah, A.R. Shah, Expert Opin. Drug Saf. 8 (2009) 191–202. doi: 10.1517/14740330902733961
51. [51]
  C.C. Meyer, K.A. Calis, L.B. Burke, C.A. Walawander, T.H. Grasela, Pharmacotherapy. 17 (1997) 729–736.
52. [52]
  O. Abdel-Rahman, Clin. Colorectal Cancer18 (2019) 58–63. doi: 10.1016/j.clcc.2018.10.006
53. [53]
  L. Heinzerling, P.A. Ott, F.S. Hodi, et al., J. Immunother. Cancer4 (2016) 50. doi: 10.1186/s40425-016-0152-y
54. [54]
  F. Inayat, M. Masab, S. Gupta, W. Ullah, BMJ Case Rep. 2018 (2018) bcr-2017-223252. doi: 10.1136/bcr-2017-223252
55. [55]
  H. Läubli, C. Balmelli, M. Bossard, et al., J. Immunother. Cancer3 (2015) 11. doi: 10.1186/s40425-015-0057-1
56. [56]
  M. Cohen, S. Mustafa, I. Elkherpitawy, M. Meleka, JACC Case Rep. 2 (2020) 426–430. doi: 10.1016/j.jaccas.2019.12.045
57. [57]
  M. Escudier, J. Cautela, N. Malissen, et al., Circulation 136 (2017) 2085–2087. doi: 10.1161/CIRCULATIONAHA.117.030571
58. [58]
  D.B. Johnson, J.M. Balko, M.L. Compton, et al., N. Engl. J. Med. 375 (2016) 1749–1755. doi: 10.1056/NEJMoa1609214
59. [59]
  G.T. Giblin, C. Dennehy, H. Featherstone, et al., Circ. Heart Fail. 14 (2021) e007524. doi: 10.1161/CIRCHEARTFAILURE.120.007524
60. [60]
  J.R. Carver, C.L. Shapiro, A. Ng, et al., J. Clin. Oncol. 25 (2007) 3991–4008. doi: 10.1200/JCO.2007.10.9777
61. [61]
  D. Montaigne, C. Hurt, R. Neviere, Biochem. Res. Int. 2012 (2012) 1–12. doi: 10.1155/2012/951539
62. [62]
  G. Takemura, H. Fujiwara, Prog. Cardiovasc. Dis. 49 (2007) 330–352. doi: 10.1016/j.pcad.2006.10.002
63. [63]
  J.F. Halazun, H.R. Wagner, J.F. Gaeta, L.F. Sinks, Cancer 33 (1974) 545–554. doi: 10.1002/1097-0142(197402)33:2<545::AID-CNCR2820330233>3.0.CO;2-M
64. [64]
  H.F. Fernandez, Z. Sun, X. Yao, et al., N. Engl. J. Med. 361 (2009) 1249–1259. doi: 10.1056/NEJMoa0904544
65. [65]
  M. Ryberg, D. Nielsen, G. Cortese, et al., JNCI J. Natl. Cancer Inst. 100 (2008) 1058–1067. doi: 10.1093/jnci/djn206
66. [66]
  M. Campone, P. Fumoleau, E. Bourbouloux, P. Kerbrat, H. Roché, Crit. Rev. Oncol. Hematol. 55 (2005) 167–175. doi: 10.1016/j.critrevonc.2005.04.003
67. [67]
  Y.J.L. Kamm, D.J.T. Wagener, I.M.C.M. Rietjens, C.J.A. Punt, Anticancer Drugs9 (1998) 371–380. doi: 10.1097/00001813-199806000-00001
68. [68]
  L.P. Molteni, I. Rampinelli, M. Cergnul, et al., Breast J. 16 (Suppl 1) (2010) S45–S48. doi: 10.1111/j.1524-4741.2010.01004.x
69. [69]
  S.Y. Zafar, Hirsch, Cancer Manag. Res. 3 (2011) 79.
70. [70]
  A. Polk, M. Vaage-Nilsen, K. Vistisen, D.L. Nielsen, Cancer Treat. Rev. 39 (2013) 974–984. doi: 10.1016/j.ctrv.2013.03.005
71. [71]
  J.J. Monsuez, J.C. Charniot, N. Vignat, J.Y. Artigou, Int. J. Cardiol. 144 (2010) 3–15. doi: 10.1016/j.ijcard.2010.03.003
72. [72]
  N. Heinrich, M. Born, E. Hoebert, et al., Vasa39 (2010) 271–273. doi: 10.1024/0301-1526/a000042
73. [73]
  A. González Del Alba, J. Á. Arranz, J. Puente, et al., Crit. Rev. Oncol. Hematol. 113 (2017) 171–190. doi: 10.1016/j.critrevonc.2017.03.010
74. [74]
  H.M. Khaled, H.E. Shafik, M.S. Zabhloul, et al., Clin. Genitourin. Cancer12 (2014) e233–e240. doi: 10.1016/j.clgc.2014.04.002
75. [75]
  S.M. Ewer, M.S. Ewer, Drug Saf. 31 (2008) 459–467. doi: 10.2165/00002018-200831060-00002
76. [76]
  Z. Mitri, T. Constantine, R. O'Regan, Chemother. Res. Pract. 2012 (2012) 743193.
77. [77]
  G.M. Keating, Drugs 74 (2014) 1891–1925. doi: 10.1007/s40265-014-0302-9
78. [78]
  R.A. Burger, M.F. Brady, M.A. Bookman, et al., N. Engl. J. Med. 365 (2011) 2473–2483. doi: 10.1056/NEJMoa1104390
79. [79]
  K.D. Miller, L.I. Chap, F.A. Holmes, et al., J. Clin. Oncol. 23 (2005) 792–799. doi: 10.1200/JCO.2005.05.098
80. [80]
  H.I. Hurwitz, L. Fehrenbacher, J.D. Hainsworth, et al., J. Clin. Oncol. 23 (2005) 3502–3508. doi: 10.1200/JCO.2005.10.017
81. [81]
  Z. CHEN, D. AI, Mol. Clin. Oncol. 4 (2016) 675–681. doi: 10.3892/mco.2016.800
82. [82]
  J.T. Hartmann, M. Haap, H.G. Kopp, H.P. Lipp, Curr. Drug Metab. 10 (2009) 470–81. doi: 10.2174/138920009788897975
83. [83]
  T.F. Chu, M.A. Rupnick, R. Kerkela, et al., Lancet370 (2007) 2011–2019. doi: 10.1016/S0140-6736(07)61865-0
84. [84]
  D. Di Lisi, F. Bonura, F. Macaione, et al., Anticancer. Drugs. 22 (2011) 468–472. doi: 10.1097/CAD.0b013e3283443704
85. [85]
  M.L. Telli, R.M. Witteles, G.A. Fisher, S. Srinivas, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 19 (2008) 1613–1618. doi: 10.1093/annonc/mdn168
86. [86]
  Z. Xu, S. Cang, T. Yang, D. Liu, Hematol. Rep. 1 (2009) 4. doi: 10.4081/hr.2009.e4
87. [87]
  Z. Xu, Y. Jin, H. Yan, et al., Toxicol. Lett. 296 (2018) 39–47. doi: 10.1016/j.toxlet.2018.08.003
88. [88]
  H. Kantarjian, R. Pasquini, N. Hamerschlak, et al., Blood 109 (2007) 5143–5150. doi: 10.1182/blood-2006-11-056028
89. [89]
  R.J. Motzer, K. Penkov, J. Haanen, et al., N. Engl. J. Med. 380 (2019) 1103–1115. doi: 10.1056/nejmoa1816047
90. [90]
  M. Escudier, J. Cautela, N. Malissen, et al., Circulation 136 (2017) 2085–2087. doi: 10.1161/CIRCULATIONAHA.117.030571
91. [91]
  E.B. Garon, N.A. Rizvi, R. Hui, et al., N. Engl. J. Med. 372 (2015) 2018–2028. doi: 10.1056/NEJMoa1501824
92. [92]
  N. Shaverdian, A.E. Lisberg, K. Bornazyan, et al., Lancet. Oncol. 18 (2017) 895–903. doi: 10.1016/S1470-2045(17)30380-7
93. [93]
  L. Hofmann, A. Forschner, C. Loquai, et al., Eur. J. Cancer60 (2016) 190–209. doi: 10.1016/j.ejca.2016.02.025
94. [94]
  S.A. Thomas, U.S. Pharm. 42 (2017) HS24–HS33.
95. [95]
  S.H. Armenian, M.M. Hudson, R.L. Mulder, et al., Lancet Oncol. 16 (2015) e123–e136. doi: 10.1016/S1470-2045(14)70409-7
96. [96]
  K.C. Oeffinger, A.C. Mertens, C.A. Sklar, et al., N. Engl. J. Med. 355 (2006) 1572–1582. doi: 10.1056/NEJMsa060185
97. [97]
  G.T. Armstrong, Q. Liu, Y. Yasui, et al., J. Clin. Oncol. 27 (2009) 2328–2338. doi: 10.1200/JCO.2008.21.1425
98. [98]
  J. López-Sendón, C. Álvarez-Ortega, P. Zamora Auñon, et al., Eur. Heart J. 41 (2020) 1720–1729. doi: 10.1093/eurheartj/ehaa006
99. [99]
  A. Seraphim, M. Westwood, A.N. Bhuva, et al., Curr. Treat. Options Oncol. 20 (2019) 73. doi: 10.1007/s11864-019-0672-z
100. [100]
  R.S. Jiji, C.M. Kramer, M. Salerno, J. Nucl. Cardiol. 19 (2012) 377–388. doi: 10.1007/s12350-012-9512-2
101. [101]
  G. Panjrath, D. Jain, J. Nucl. Cardiol. 13 (2006) 415–426. doi: 10.1016/j.nuclcard.2006.03.002
102. [102]
  M. Habibian, A.R. Lyon, Eur. Hear. J. Suppl. 21 (2019) M44–M49. doi: 10.1093/eurheartj/suz230
103. [103]
  J.L. Zamorano, P. Lancellotti, D. Rodriguez Muñoz, et al., Eur. J. Heart Fail. 19 (2017) 9–42. doi: 10.1002/ejhf.654
104. [104]
  V.C. Simbre, S.A. Duffy, G.H. Dadlani, T.L. Miller, S.E. Lipshultz, Pediatr. Drugs7 (2005) 187–202. doi: 10.2165/00148581-200507030-00005
105. [105]
  D.K. Shakir, K.I. Rasul, J. Clin. Med. Res. 1 (2009) 8–12.
106. [106]
  I. Raber, S. Warack, J. Kanduri, et al., Oncologist25 (2020) e606–e609. doi: 10.1634/theoncologist.2019-0762
107. [107]
  V.B. Pai, M.C. Nahata, Drug Saf. 22 (2000) 263–302. doi: 10.2165/00002018-200022040-00002
108. [108]
  E. Sadurska, Pediatr. Cardiol. 36 (2015) 1112–1119. doi: 10.1007/s00246-015-1176-7
109. [109]
  R. Madonna, Rev. Española Cardiol. (English Ed. )70 (2017) 576–582. doi: 10.1016/j.recesp.2016.12.032
110. [110]
  K. Strimbu, J.A. Tavel, Curr. Opin. HIV AIDS5 (2010) 463–466. doi: 10.1097/COH.0b013e32833ed177
111. [111]
  S. Moazeni, M. Cadeiras, E.H. Yang, M.C. Deng, K. Nguyen, Clin. Transl. Med. 6 (2017) 1–12. doi: 10.1109/NAPS.2017.8107248
112. [112]
  V.S. Mahajan, P. Jarolim, Circulation. 124 (2011) 2350–2354. doi: 10.1161/CIRCULATIONAHA.111.023697
113. [113]
  D. Cardinale, A. Colombo, R. Torrisi, et al., J. Clin. Oncol. 28 (2010) 3910–3916. doi: 10.1200/JCO.2009.27.3615
114. [114]
  T. Reichlin, W. Hochholzer, S. Bassetti, et al., N. Engl. J. Med. 361 (2009) 858–867. doi: 10.1056/NEJMoa0900428
115. [115]
  S. Mythili, N. Malathi, Biomed. Rep. 3 (2015) 743–748. doi: 10.3892/br.2015.500
116. [116]
  H.K. Walker, W.D. Hall, J.W. Hurst, et al., Clinical Methods: The History, Physical, and Laboratory Examinations, 3rd Edition, Butterworths, Boston, 1990.
117. [117]
  T. Reichlin, R. Twerenbold, M. Reiter, et al., Am. J. Med. 125 (2012) 1205. el. -1213. e1.
118. [118]
  A. Samman Tahhan, P. Sandesara, S.S. Hayek, et al., J. Am. Heart Assoc. 7 (2018) e007914. doi: 10.1161/JAHA.117.007914
119. [119]
  G.V. Halade, Y. -. F. Jin, M.L. Lindsey, Pharmacol. Ther. 139 (2013) 32–40. doi: 10.1016/j.pharmthera.2013.03.009
120. [120]
  D.R. Wagner, C. Delagardelle, I. Ernens, et al., J. Card. Fail. 12 (2006) 66–72. doi: 10.1016/j.cardfail.2005.08.002
121. [121]
  S. Blankenberg, H.J. Rupprecht, O. Poirier, et al., Circulation 107 (2003) 1579–1585. doi: 10.1161/01.CIR.0000058700.41738.12
122. [122]
  Q. Liu, Z. Yu, S. Yuan, et al., Oncotarget. 8 (2017) 13048–13058. doi: 10.18632/oncotarget.14369
123. [123]
  R.A. de Boer, L. Yu, D.J. van Veldhuisen, Curr. Heart Fail. Rep. 7 (2010) 1–8. doi: 10.1007/s11897-010-0004-x
124. [124]
  J.E. Ho, C. Liu, A. Lyass, et al., J. Am. Coll. Cardiol. 60 (2012) 1249–1256. doi: 10.1016/j.jacc.2012.04.053
125. [125]
  I. Iurisci, N. Tinari, C. Natoli, et al., Clin. Cancer Res. 6 (2000) 1389–93.
126. [126]
  V. Panagopoulou, S. Deftereos, C. Kossyvakis, et al., Curr. Top. Med. Chem. 13 (2013) 82–94. doi: 10.2174/1568026611313020002
127. [127]
  M.L. Novack, M.E. Zevitz, Natriuretic Peptide B Type Test, StatPearls Publishing, Treasure Island (FL), 2020. https://www.ncbi.nlm.nih.gov/books/NBK556136/.
128. [128]
  R.Y. Xu, X.F. Zhu, Y. Yang, P. Ye, J. Geriatr. Cardiol. 10 (2013) 102–109.
129. [129]
  N.E. Ibrahim, J.L. Januzzi, Circ. Res. 123 (2018) 614–629. doi: 10.1161/circresaha.118.312706
130. [130]
  D.A. Morrow, C.P. Cannon, R.L. Jesse, et al., Circulation 115 (2007) e356–e375.
131. [131]
  C. deFilippi, JAMA 290 (2003) 353. doi: 10.1001/jama.290.3.353
132. [132]
  S.M. Nehring, A. Goyal, P. Bansal, B.C. Patel, C Reactive Protein, StatPearls Publishing, Treasure Island (FL), 2021. https://www.ncbi.nlm.nih.gov/books/NBK556136/.
133. [133]
  J. Mlabasati, J. Singer, A. Conigliaro, P. Selvan, S. Levine, Stroke48 (2017) e356–e375.
134. [134]
  A.A. Onitilo, J.M. Engel, R.V. Stankowski, et al., Breast Cancer Res. Treat. 134 (2012) 291–298. doi: 10.1007/s10549-012-2039-z
135. [135]
  S.S. Bassuk, N. Rifai, P.M. Ridker, Curr. Probl. Cardiol. 29 (2004) 439–493.
136. [136]
  M.J. Caslake, C.J. Packard, Nat. Clin. Pract. Cardiovasc. Med. 2 (2005) 529–535. doi: 10.1038/ncpcardio0321
137. [137]
  R.B. Lanman, R.L. Wolfert, J.K. Fleming, et al., Prev. Cardiol. 9 (2006) 138–143. doi: 10.1111/j.1520-037X.2006.05547.x
138. [138]
  U. Ikeda, T. Ito, K. Shimada, Clin. Cardiol. 24 (2001) 701–704. doi: 10.1002/clc.4960241103
139. [139]
  M. Alecu, L. Geleriu, G. Coman, L. Gălăţescu, Rom. J. Intern. Med. 36 (1998) 251–259.
140. [140]
  P.M. Ridker, Circ. Res. 118 (2016) 145–156. doi: 10.1161/CIRCRESAHA.115.306656
141. [141]
  L.F. Buckley, A. Abbate, Eur. Heart J. 39 (2018) 2063–2069. doi: 10.1093/eurheartj/ehy128
142. [142]
  A. Trpkovic, I. Resanovic, J. Stanimirovic, et al., Crit. Rev. Clin. Lab. Sci. 52 (2015) 70–85. doi: 10.3109/10408363.2014.992063
143. [143]
  J.D. Otvos, D. Collins, D.S. Freedman, et al., Circulation. 113 (2006) 1556–1563. doi: 10.1161/CIRCULATIONAHA.105.565135
144. [144]
  B.I. Coculescu, G.V. Dincă, C. Bălăeţ, et al., J. Enzyme Inhib. Med. Chem. 33 (2018) 1292–1298. doi: 10.1080/14756366.2018.1499626
145. [145]
  D.A. Morrow, M.S. Sabatine, M. -. L. Brennan, et al., Eur. Heart J. 29 (2008) 1096–1102. doi: 10.1093/eurheartj/ehn071
146. [146]
  W. Bradham, Cardiovasc. Res. 53 (2002) 822–830. doi: 10.1016/S0008-6363(01)00503-X
147. [147]
  G. Torre-Amione, S. Kapadia, J. Lee, et al., Circulation. 93 (1996) 704–711. doi: 10.1161/01.CIR.93.4.704
148. [148]
  G.K. Wang, J.Q. Zhu, J.T. Zhang, et al., Eur. Heart J. 31 (2010) 659–666. doi: 10.1093/eurheartj/ehq013
149. [149]
  X. Ji, R. Takahashi, Y. Hiura, et al., Clin. Chem. 55 (2009) 1944–1949. doi: 10.1373/clinchem.2009.125310
150. [150]
  D.A. Chistiakov, A.A. Melnichenko, A.N. Orekhov, Y.V. Bobryshev, Biochimie 132 (2017) 19–27. doi: 10.1016/j.biochi.2016.10.010
151. [151]
  T.E. Callis, K. Pandya, H.Y. Seok, et al., J. Clin. Invest. 119 (2009) 2772–2786. doi: 10.1172/JCI36154
152. [152]
  C. Ruggeri, S. Gioffré, M. Chiesa, et al., Dis. Markers. 2018 (2018) 1–9. doi: 10.1155/2018/8395651
153. [153]
  A. Sachinidis, EXCLI J. 15 (2016) 163–165.
154. [154]
  E. Article, Russ. J. Cardiol. (2017) 105–139.
155. [155]
  J.D. Schuijf, D. Poldermans, L.J. Shaw, et al., Eur. J. Nucl. Med. Mol. Imaging33 (2006) 93–104. doi: 10.1007/s00259-005-1965-y
156. [156]
  A. Soufer, L.A. Baldassarre, Curr. Treat. Options Cardiovasc. Med. 21 (2019) 28. doi: 10.1007/s11936-019-0732-5
157. [157]
  C. Jenkins, K. Bricknell, L. Hanekom, T.H. Marwick, J. Am. Coll. Cardiol. 44 (2004) 878–886. doi: 10.1016/j.jacc.2004.05.050
158. [158]
  K. Ylänen, T. Poutanen, T. Savukoski, A. Eerola, K. Vettenranta, Acta Paediatr. 104 (2015) 313–319. doi: 10.1111/apa.12862
159. [159]
  A. Banerjee, D.R. Newman, A. Van den Bruel, C. Heneghan, Int. J. Clin. Pract. 66 (2012) 477–492. doi: 10.1111/j.1742-1241.2012.02900.x
160. [160]
  P. Thavendiranathan, F. Poulin, K.D. Lim, et al., J. Am. Coll. Cardiol. 63 (2014) 2751–2768. doi: 10.1016/j.jacc.2014.01.073
161. [161]
  S.H. Armenian, C. Lacchetti, D. Lenihan, J. Oncol. Pract. 13 (2017) 270–275. doi: 10.1200/JOP.2016.018770
162. [162]
  M.W. von Ballmoos, B. Haring, P. Juillerat, H. Alkadhi, Ann. Intern. Med. 154 (2011) 413. doi: 10.7326/0003-4819-154-6-201103150-00007
163. [163]
  J. Sivapackiam, S. Kabra, S. Speidel, et al., PLoS ONE. 14 (2019) e0215579. doi: 10.1371/journal.pone.0215579
164. [164]
  S.P. McCluskey, A. Haslop, C. Coello, et al., J. Nucl. Med. 60 (2019) 1750–1756. doi: 10.2967/jnumed.119.226787
165. [165]
  M. Bauckneht, G. Ferrarazzo, F. Fiz, et al., J. Nucl. Med. 58 (2017) 1638–1645. doi: 10.2967/jnumed.117.191122
166. [166]
  A. Soufer, C. Liu, M.L. Henry, L.A. Baldassarre, J. Nucl. Cardiol. 27 (2020) 1210–1224. doi: 10.1007/s12350-019-01671-6
167. [167]
  M. Bauckneht, F. Pastorino, P. Castellani, et al., J. Nucl. Cardiol. 27 (2020) 2183–2194. doi: 10.1007/s12350-019-01618-x
168. [168]
  N. Kalay, E. Basar, I. Ozdogru, et al., J. Am. Coll. Cardiol. 48 (2006) 2258–2262. doi: 10.1016/j.jacc.2006.07.052
169. [169]
  H. Su, N. Gorodny, L.F. Gomez, et al., Circ. Cardiovasc. Imaging8 (2015) e001952. doi: 10.1161/CIRCIMAGING.114.001952
170. [170]
  M. Totzeck, J. Siebermair, T. Rassaf, C. Rischpler, Eur. Heart J. 41 (2020) 1060.
171. [171]
  P. Lancellotti, T.M. Suter, T. López-Fernández, et al., Eur. Heart J. 40 (2019) 1756–1763. doi: 10.1093/eurheartj/ehy453
172. [172]
  T. Rassaf, M. Totzeck, J. Thorac. Dis. 10 (2018) S4386–S4390. doi: 10.21037/jtd.2018.11.110
173. [173]
  J. Moslehi, K. Fujiwara, T. Guzik, Cardiovasc. Res. 115 (2019) 819–823. doi: 10.1093/cvr/cvz048
174. [174]
  J. Alexandre, J. Cautela, S. Ederhy, et al., J. Am. Heart Assoc. 9 (2020) e018403. doi: 10.1161/JAHA.120.018403
175. [175]
  S. Dent, S. Hopkins, N. Graham, et al., Cardiol. Res. Pract. 2012 (2012) 1–5. doi: 10.1155/2012/135819
176. [176]
  J.R. Brahmer, C. Lacchetti, B.J. Schneider, et al., J. Clin. Oncol. 36 (2018) 1714–1768. doi: 10.1200/jco.2017.77.6385
177. [177]
  J.B.A.G. Haanen, F. Carbonnel, C. Robert, et al., Ann. Oncol. 28 (2017) iv119–iv142. doi: 10.1093/annonc/mdx225
178. [178]
  G. Curigliano, D. Lenihan, M. Fradley, et al., Ann. Oncol. 31 (2020) 171–190. doi: 10.1016/j.annonc.2019.10.023
179. [179]
  G. Curigliano, D. Cardinale, T. Suter, et al., Ann. Oncol. 23 (2012) vii155–vii166. doi: 10.1093/annonc/mds293
180. [180]
  D. Cardinale, A. Colombo, M.T. Sandri, et al., Circulation 114 (2006) 2474–2481. doi: 10.1161/CIRCULATIONAHA.106.635144
181. [181]
  D. Cardinale, A. Colombo, G. Lamantia, et al., J. Am. Coll. Cardiol. 55 (2010) 213–220. doi: 10.1016/j.jacc.2009.03.095
182. [182]
  T. Eschenhagen, T. Force, M.S. Ewer, et al., Eur. J. Heart Fail. 13 (2011) 1–10. doi: 10.1093/eurjhf/hfq213
183. [183]
  C.W. Yancy, M. Jessup, B. Bozkurt, et al., Circulation 136 (2017) e137–e161. doi: 10.1161/CIR.0000000000000509
184. [184]
  S.R. Ommen, S. Mital, M.A. Burke, et al., Circulation 142 (2020) e558–e631.
185. [185]
  P.J. Oliveira, J.A. Bjork, M.S. Santos, et al., Toxicol. Appl. Pharmacol. 200 (2004) 159–168. doi: 10.1016/j.taap.2004.04.005
186. [186]
  M. Colombo, G. Raposo, C. Théry, Annu. Rev. Cell Dev. Biol. 30 (2014) 255–289. doi: 10.1146/annurev-cellbio-101512-122326
187. [187]
  S. Deng, T. Yan, C. Jendrny, et al., BMC Cancer. 14 (2014) 842. doi: 10.1186/1471-2407-14-842
188. [188]
  R. Rodrigo, M. Libuy, F. Feliú, D. Hasson, Biomed Res. Int. 2013 (2013) 1–15.
189. [189]
  J.M. Upston, P.K. Witting, A.J. Brown, R. Stocker, J.F. Keaney, Free Radic. Biol. Med. 31 (2001) 1245–1253. doi: 10.1016/S0891-5849(01)00721-3
190. [190]
  A.C. Terentis, S.R. Thomas, J.A. Burr, D.C. Liebler, R. Stocker, Circ. Res. 90 (2002) 333–339. doi: 10.1161/hh0302.104454
191. [191]
  M. Levine, S.J. Padayatty, M.G. Espey, Adv. Nutr. 2 (2011) 78–88. doi: 10.3945/an.110.000109
192. [192]
  E. Hao, P. Mukhopadhyay, Z. Cao, et al., Mol. Med. 21 (2015) 38–45. doi: 10.2119/molmed.2014.00261
193. [193]
  Y. Liu, A. Asnani, L. Zou, et al., Sci. Transl. Med. 6 (2014) 266ra170.
194. [194]
  I. Sargin, L. Akyuz, M. Kaya, et al., Int. J. Biol. Macromol. 105 (2017) 749–756. doi: 10.1016/j.ijbiomac.2017.07.093
195. [195]
  A. Takahashi, Y. Yamamoto, M. Yasunaga, et al., Cancer Sci. 104 (2013) 920–5. doi: 10.1111/cas.12153
196. [196]
  P.W. Burridge, Y.F. Li, E. Matsa, et al., Nat. Med. 22 (2016) 547–556. doi: 10.1038/nm.4087
197. [197]
  Y. Liu, D. Liu, J. Shi, R.S. Langer, Cancer nanotechnology, in: R.C. Bast Jr, C.M. Croce, W.N. Hait, et al. (Eds. ), Holland-Frei Cancer Med. (9th Ed. ), John Wiley & Sons, Inc., Hoboken, 2017, pp. 1–7.
198. [198]
  R.K. Tekade, R. Maheshwari, N. Soni, M. Tekade, M.B. Chougule, Nanotechnology for the development of nanomedicine, in: V. Mishra, P. Kesharwani, MCIM Amin, A. Iyer (Eds. ), Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes, Elsevier, 2017, pp. 3–61.
199. [199]
  M. Slingerland, H. -. J. Guchelaar, H. Gelderblom, Drug Discov. Today. 17 (2012) 160–166. doi: 10.1016/j.drudis.2011.09.015
200. [200]
  J.G. Reynolds, E. Geretti, B.S. Hendriks, et al., Toxicol. Appl. Pharmacol. 262 (2012) 1–10. doi: 10.1016/j.taap.2012.04.008
201. [201]
  A.M. Rahman, S.W. Yusuf, M.S. Ewer, Int. J. Nanomedicine. 2 (2007) 567–583.
202. [202]
  T. Olusanya, R. Haj Ahmad, D. Ibegbu, J. Smith, A. Elkordy, Molecules. 23 (2018) 907. doi: 10.3390/molecules23040907
203. [203]
  S.R. Jean, D.V. Tulumello, C. Riganti, et al., ACS Chem. Biol. 10 (2015) 2007–2015. doi: 10.1021/acschembio.5b00268
204. [204]
  S. -. S. Sheu, D. Nauduri, M.W. Anders, Biochim. Biophys. Acta: Mol. Basis Dis. 1762 (2006) 256–265. doi: 10.1016/j.bbadis.2005.10.007
205. [205]
  Y. Yang, S. Karakhanova, W. Hartwig, et al., J. Cell. Physiol. 231 (2016) 2570–2581. doi: 10.1002/jcp.25349
206. [206]
  C. Riganti, B. Rolando, J. Kopecka, et al., Mol. Pharm. 10 (2013) 161–174. doi: 10.1021/mp300311b
207. [207]
  C. Feng, Z. Wang, C. Jiang, et al., Int. J. Pharm. 457 (2013) 158–167. doi: 10.1016/j.ijpharm.2013.07.079
208. [208]
  V.P. Torchilin, Nat. Rev. Drug Discov. 13 (2014) 813–827. doi: 10.1038/nrd4333
209. [209]
  E. Alemzadeh, A. Dehshahri, A.R. Dehghanian, et al., Colloids Surf. B: Biointerfaces174 (2019) 80–86. doi: 10.1016/j.colsurfb.2018.11.008
210. [210]
  K. Xiao, J. Luo, Y. Li, et al., J. Control. Release155 (2011) 272–281. doi: 10.1016/j.jconrel.2011.07.018
211. [211]
  A. Lucas, D. Lam, P. Cabrales, Drug Deliv. 26 (2019) 433–442. doi: 10.1080/10717544.2019.1591544
212. [212]
  W. Sun, P. Zhao, Y. Zhou, et al., Biochem. Biophys. Res. Commun. 532 (2020) 60–67. doi: 10.1016/j.bbrc.2020.05.044
213. [213]
  E. Tahover, Y.P. Patil, A.A. Gabizon, Anticancer Drugs26 (2015) 241–258. doi: 10.1097/CAD.0000000000000182
214. [214]
  R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros, The Breast18 (2009) 218–224. doi: 10.1016/j.breast.2009.05.004
215. [215]
  T. Safra, Oncologist8 (2003) 17–24. doi: 10.1634/theoncologist.8-suppl_2-17
216. [216]
  S.A. Abraham, D.N. Waterhouse, L.D. Mayer, et al., The liposomal formulation of doxorubicin, in: N. Duzgunes (Ed. ), Methods in Enzymology, Elsevier, Amsterdam, 2005, pp. 71–97.
217. [217]
  G. Caracciolo, Nanoscale. 10 (2018) 4167–4172. doi: 10.1039/C7NR07450F
218. [218]
  A. Gabizon, A. Dagan, D. Goren, Y. Barenholz, Z. Fuks, Cancer Res. 42 (1982) 4734–4739.
219. [219]
  S. -. T. Huang, Y. Wang, Y. -. H. Chen, et al., Int. J. Oncol. 53 (2018) 1105–1117.
220. [220]
  R. Zhang, Y. Zhang, Y. Zhang, et al., Asian J. Pharm. Sci. 15 (2020) 385–396. doi: 10.1016/j.ajps.2019.04.007
221. [221]
  G. Berry, M. Billingham, E. Alderman, et al., Ann. Oncol. 9 (1998) 711–716. doi: 10.1023/A:1008216430806
222. [222]
  K.B. Wallace, V.A. Sardão, P.J. Oliveira, Circ. Res. 126 (2020) 926–941. doi: 10.1161/circresaha.119.314681
223. [223]
  S. Rin Jean, D.V. Tulumello, S.P. Wisnovsky, et al., ACS Chem. Biol. 9 (2014) 323–333. doi: 10.1021/cb400821p
224. [224]
  G.R. Chamberlain, D.V. Tulumello, S.O. Kelley, ACS Chem. Biol. 8 (2013) 1389–1395. doi: 10.1021/cb400095v
225. [225]
  J. Abe, Y. Yamada, A. Takeda, H. Harashima, J. Control. Release. 269 (2018) 177–188. doi: 10.1016/j.jconrel.2017.11.024
226. [226]
  D. Graham, N.N. Huynh, C.A. Hamilton, et al., Hypertension 54 (2009) 322–328. doi: 10.1161/HYPERTENSIONAHA.109.130351
227. [227]
  M. Israel, E.J. Modest, E. Frei, Cancer Res. 35 (1975) 1365–1368.
228. [228]
  S.P. Kuruvilla, G. Tiruchinapally, A.C. Crouch, M.E.H. ElSayed, J.M. Greve, PLoS ONE12 (2017) e0181944. doi: 10.1371/journal.pone.0181944
229. [229]
  S. Wagner, F. Rothweiler, M.G. Anhorn, et al., Biomaterials 31 (2010) 2388–2398. doi: 10.1016/j.biomaterials.2009.11.093
230. [230]
  F. Kratz, B. Elsadek, J. Control. Release. 161 (2012) 429–445. doi: 10.1016/j.jconrel.2011.11.028
231. [231]
  B. Zhang, S. Wan, X. Peng, et al., J. Mater. Chem. B8 (2020) 3939–3948. doi: 10.1039/d0tb00327a
232. [232]
  A. Yuan, J. Wu, C. Song, et al., J. Pharm. Sci. 102 (2013) 1626–1635. doi: 10.1002/jps.23455
233. [233]
  G. Marslin, A.M. Revina, V.K.M. Khandelwal, et al., Int. J. Nanomed. 10 (2015) 3163–70.
234. [234]
  L. Zhang, K. Zhu, H. Zeng, et al., Int. J. Nanomed. 14 (2019) 6061–6071. doi: 10.2147/ijn.s211130
235. [235]
  Y. Yang, Q. Guo, J. Peng, et al., J. Biomed. Nanotechnol. 12 (2016) 1963–1974. doi: 10.1166/jbn.2016.2298
236. [236]
  Y. Ling, K. Wei, Y. Luo, X. Gao, S. Zhong, Biomaterials 32 (2011) 7139–7150. doi: 10.1016/j.biomaterials.2011.05.089
237. [237]
  C. Tassa, S.Y. Shaw, R. Weissleder, Acc. Chem. Res. 44 (2011) 842–852. doi: 10.1021/ar200084x
238. [238]
  H. Arami, Z. Stephen, O. Veiseh, M. Zhang, Adv. Polym. Sci. 243 (2011) 163–184. doi: 10.1007/12_2011_121
239. [239]
  I. Slowing, J. Viveroescoto, C. Wu, V. Lin, Adv. Drug Deliv. Rev. 60 (2008) 1278–1288. doi: 10.1016/j.addr.2008.03.012
240. [240]
  S.D. Brown, P. Nativo, J.A. Smith, et al., J. Am. Chem. Soc. 132 (2010) 4678–4684. doi: 10.1021/ja908117a
241. [241]
  S. Acharya, S.K. Sahoo, Adv. Drug Deliv. Rev. 63 (2011) 170–83. doi: 10.1016/j.addr.2010.10.008
242. [242]
  C.P. Silveira, L.M. Apolinário, W.J. Fávaro, A.J. Paula, N. Durán, ACS Biomater. Sci. Eng. 2 (2016) 1190–1199. doi: 10.1021/acsbiomaterials.6b00241
243. [243]
  W. Liu, F. Wang, Y. Zhu, et al., Molecules23 (2018) 3082. doi: 10.3390/molecules23123082
244. [244]
  C.T.H. Nguyen, R.I. Webb, L.K. Lambert, et al., ACS Appl. Mater. Interfaces9 (2017) 9470–9483. doi: 10.1021/acsami.7b00411
245. [245]
  M.Y. Hanafi-Bojd, S.A. Moosavian Kalat, S.M. Taghdisi, et al., Drug Dev. Ind. Pharm. 44 (2018) 13–18. doi: 10.1080/03639045.2017.1371734
246. [246]
  L. Pascual, C. Cerqueira-Coutinho, A. García-Fernández, et al., Nanomedicine: Nanotechnol. Biol. Med. 13 (2017) 2495–2505. doi: 10.1016/j.nano.2017.08.006
247. [247]
  D. Dréau, L.J. Moore, M.P. Alvarez-Berrios, et al., J. Biomed. Nanotechnol. 12 (2016) 2172–2184. doi: 10.1166/jbn.2016.2318
248. [248]
  J. -. X. Wang, X. -. J. Zhang, C. Feng, et al., Cell Death Dis. 6 (2015) e1677–e1677.
249. [249]
  O.J. Arola, A. Saraste, K. Pulkki, et al., Cancer Res. 60 (2000) 1789–1792.
250. [250]
  B. Cote, L.J. Carlson, D.A. Rao, A.W.G. Alani, J. Control. Release. 213 (2015) 128–133. doi: 10.1016/j.jconrel.2015.06.040
251. [251]
  A. Ucar, S.K. Gupta, J. Fiedler, et al., Nat. Commun. 3 (2012) 1078. doi: 10.1038/ncomms2090
252. [252]
  S.K. Gupta, A. Garg, P. Avramopoulos, et al., Mol. Ther. 27 (2019) 17–28. doi: 10.1016/j.ymthe.2018.11.004
253. [253]
  Q.T.H. Shubhra, K. Guo, Y. Liu, et al., Acta Biomater. 131 (2021) 493–507. doi: 10.1016/j.actbio.2021.06.016
254. [254]
  L.J.C. Albuquerque, V. Sincari, A. Jäger, et al., J. Control. Release332 (2021) 529–538. doi: 10.1016/j.jconrel.2021.03.013
255. [255]
  X. Wang, L. Zeng, S. Tu, F. Ye, Z. Zhang, Arab. J. Chem. 14 (2021) 103142. doi: 10.1016/j.arabjc.2021.103142
256. [256]
  E. Ordonez, L.L. Kendrick-Williams, E. Harth, Eur. Polym. J. 143 (2021) 110210. doi: 10.1016/j.eurpolymj.2020.110210
257. [257]
  Y. Wang, Q. Ma, S. Zhang, et al., Front. Pharmacol. 11 (2020) 186. doi: 10.3389/fphar.2020.00186
258. [258]
  D.W. Grainger, Int. J. Pharm. 454 (2013) 521–524. doi: 10.1016/j.ijpharm.2013.04.061
259. [259]
  T.T. Hoang Thi, E.H. Pilkington, D.H. Nguyen, et al., Polymers (Basel)12 (2020) 298. doi: 10.3390/polym12020298
260. [260]
  P. Ma, R.J. Mumper, J. Nanomed. Nanotechnol. 4 (2013) 1000164.
261. [261]
  H. Yuan, H. Guo, X. Luan, et al., Mol. Pharm. 17 (2020) 2275–2286. doi: 10.1021/acs.molpharmaceut.9b01221
262. [262]
  F. Petrelli, K. Borgonovo, S. Barni, Expert Opin. Pharmacother. 11 (2010) 1413–32. doi: 10.1517/14656561003796562
263. [263]
  S.R. Deka, P. Verma, R. Singh, P. Kumar, Nano-Structures & Nano-Objects26 (2021) 100688.
264. [264]
  A. Jain, S. Jain, Crit. Rev. Ther. Drug Carr. Syst. 25 (2008) 403–447. doi: 10.1615/CritRevTherDrugCarrierSyst.v25.i5.10
265. [265]
  C. He, Z. Huang, X. Han, et al., J. Macromol. Sci. Part B45 (2006) 515–524. doi: 10.1080/00222340600769832
266. [266]
  H.K. Makadia, S.J. Siegel, Polymers (Basel)3 (2011) 1377–1397. doi: 10.3390/polym3031377
1. [1]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
2. [2]
  Yao-Hua Gu , Yu Chen , Qing Li , Neng-Bin Xie , Xue Xing , Jun Xiong , Min Hu , Tian-Zhou Li , Ke-Yu Yuan , Yu Liu , Tang Tang , Fan He , Bi-Feng Yuan . Metabolome profiling by widely-targeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of chronic kidney disease. Chinese Chemical Letters, 2024, 35(11): 109627-. doi: 10.1016/j.cclet.2024.109627
3. [3]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
4. [4]
  Cheng Guo , Xiaoxiao Zhang , Xiujuan Hong , Yiqiu Hu , Lingna Mao , Kezhi Jiang . Graphene as adsorbent for highly efficient extraction of modified nucleosides in urine prior to liquid chromatography-tandem mass spectrometry analysis. Chinese Chemical Letters, 2024, 35(4): 108867-. doi: 10.1016/j.cclet.2023.108867
5. [5]
  Xiaoxiao Wang , Bolun Wang , Fenfen Ji , Jie Yan , Jiacheng Fang , Doudou Zhang , Ji Xu , Jing Ji , Xinran Hao , Hemi Luan , Yanjun Hong , Shulan Qiu , Min Li , Zhu Yang , Wenlan Liu , Xiaodong Cai , Zongwei Cai . Discovery of plasma biomarkers for Parkinson’s disease diagnoses based on metabolomics and lipidomics. Chinese Chemical Letters, 2024, 35(11): 109653-. doi: 10.1016/j.cclet.2024.109653
6. [6]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
7. [7]
  Chuyu Huang , Zhishan Liu , Linping Zhao , Zuxiao Chen , Rongrong Zheng , Xiaona Rao , Yuxuan Wei , Xin Chen , Shiying Li . Metal-coordinated oxidative stress amplifier to suppress tumor growth combined with M2 macrophage elimination. Chinese Chemical Letters, 2024, 35(12): 109696-. doi: 10.1016/j.cclet.2024.109696
8. [8]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
9. [9]
  Du Liu , Yuyan Li , Hankun Zhang , Benhua Wang , Chaoyi Yao , Minhuan Lan , Zhanhong Yang , Xiangzhi Song . Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy. Chinese Chemical Letters, 2025, 36(2): 109910-. doi: 10.1016/j.cclet.2024.109910
10. [10]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
11. [11]
  Hongmei Yu , Baoxi Zhang , Meiju Liu , Cheng Xing , Guorong He , Li Zhang , Ningbo Gong , Yang Lu , Guanhua Du . Theoretical and experimental cocrystal screening of temozolomide with a series of phenolic acids, promising cocrystal coformers. Chinese Chemical Letters, 2024, 35(5): 109032-. doi: 10.1016/j.cclet.2023.109032
12. [12]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
13. [13]
  Beitong Zhu , Xiaorui Yang , Lirong Jiang , Tianhong Chen , Shuangfei Wang , Lintao Zeng . A portable and versatile fluorescent platform for high-throughput screening of toxic phosgene, diethyl chlorophosphate and volatile acyl chlorides. Chinese Chemical Letters, 2025, 36(1): 110222-. doi: 10.1016/j.cclet.2024.110222
14. [14]
  Qingyun Hu , Wei Wang , Junyuan Lu , He Zhu , Qi Liu , Yang Ren , Hong Wang , Jian Hui . High-throughput screening of high energy density LiMn_1-xFe_xPO₄ via active learning. Chinese Chemical Letters, 2025, 36(2): 110344-. doi: 10.1016/j.cclet.2024.110344
15. [15]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
16. [16]
  Jinyu Guo , Yandai Lin , Shaohua He , Yueqing Chen , Fenglu Li , Renjie Ruan , Gaoxing Pan , Hexin Nan , Jibin Song , Jin Zhang . Utilizing dual-responsive iridium(Ⅲ) complex for hepatocellular carcinoma: Integrating photoacoustic imaging with chemotherapy and photodynamic therapy. Chinese Chemical Letters, 2024, 35(9): 109537-. doi: 10.1016/j.cclet.2024.109537
17. [17]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
18. [18]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
19. [19]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
20. [20]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335

Get Citation

PDF

XML

Metrics

PDF Downloads(2)
Abstract views(759)
HTML views(30)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142